• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile: A Novel Fluorinated Compound with Promising Pharmacological Potential

5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile (CAS No. 1092460-90-6) represents a fluorinated aromatic acetonitrile derivative with unique structural features that have garnered significant attention in the field of medicinal chemistry. The compound's molecular framework combines a phenyl ring functionalized with both fluorine and trifluoromethoxy groups, along with an acetonitrile substituent, creating a highly polar and electron-deficient molecule. These structural characteristics are critical for understanding its potential applications in drug discovery and biological activity.

Recent studies in fluorine-containing organic compounds have highlighted the importance of fluorine substitution in modulating physicochemical properties such as lipophilicity, metabolic stability, and receptor binding affinity. The trifluoromethoxy group (CF₃O) in 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile contributes to enhanced hydrophobicity and electronic effects, which are essential for optimizing drug-like properties. Comparative analysis with similar fluorinated derivatives has demonstrated that this compound exhibits superior solubility and membrane permeability, making it a compelling candidate for further preclinical investigation.

Structurally, 5-Fluoro-2-(trifluoromethoxy)phenylacetonitr,ile features a phenyl ring with two distinct functional groups: a fluorine atom at the 5-position and a trifluoromethoxy group at the 2-position. The acetonitrile moiety, a common feature in many pharmaceutical agents, adds additional polarity to the molecule. This combination of functional groups creates a unique molecular profile that may enable interactions with specific biological targets, such as ion channels or enzyme active sites.

Emerging research in fluorinated aromatic compounds has revealed that the presence of multiple fluorine atoms can significantly influence the pharmacokinetic behavior of a molecule. For instance, the trifluoromethoxy group in 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile may enhance metabolic stability by reducing susceptibility to enzymatic hydrolysis. This property is particularly valuable in the development of long-acting therapeutic agents. Additionally, the fluorine atoms may modulate the molecule's ability to cross biological membranes, which is critical for achieving therapeutic concentrations in target tissues.

Recent advancements in computational drug design have facilitated the prediction of the molecular interactions of 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile with potential biological targets. Molecular docking studies suggest that this compound may exhibit affinity for certain G protein-coupled receptors (GPCRs), which are key targets for many drugs. The electronic properties of the trifluoromethoxy group may enable specific interactions with hydrophobic pockets in these receptors, potentially modulating signaling pathways associated with various physiological processes.

Experimental data from in vitro assays indicate that 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile displays moderate cytotoxicity against certain cancer cell lines, suggesting its potential as an antineoplastic agent. However, further research is needed to determine the mechanism of action and to evaluate its selectivity for cancerous versus normal cells. These findings align with broader trends in fluorinated pharmaceuticals, where the introduction of fluorine atoms is increasingly being used to enhance therapeutic efficacy while minimizing side effects.

The synthesis of 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile has been explored through several methodologies, including electrophilic substitution reactions and nucleophilic aromatic substitution. The stability of the trifluoromethoxy group under reaction conditions is a critical factor in the design of synthetic routes. Recent developments in fluorinated compound synthesis have enabled more efficient and scalable methods for producing this compound, which is essential for advancing its potential applications in drug development.

Studies on the pharmacological activity of related fluorinated compounds have provided insights into the possible mechanisms of action of 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile. For example, compounds with similar structural features have been shown to exhibit anti-inflammatory properties by modulating cytokine production. While direct evidence for such effects in 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile is limited, its structural similarity to known bioactive agents suggests that further investigation into its biological activity is warranted.

Environmental and toxicological considerations are also important in the evaluation of 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile. The presence of fluorine atoms may affect the compound's biodegradability and environmental persistence, which are critical factors in the development of sustainable pharmaceuticals. Comparative studies with other fluorinated compounds have shown that the trifluoromethoxy group can significantly influence the compound's degradation profile, highlighting the need for careful assessment of its ecological impact.

Future research on 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile should focus on elucidating its biological activity through more comprehensive in vivo studies. Additionally, exploring its potential as a lead compound for drug development could yield valuable insights into the role of fluorine substitution in modulating pharmacological properties. The continued advancement of fluorinated pharmaceuticals underscores the importance of compounds like 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile in the quest for more effective and selective therapeutic agents.

In conclusion, 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile represents an intriguing example of how fluorine substitution can influence the properties and potential applications of organic compounds. Its unique molecular structure, combined with the benefits of fluorine-containing pharmaceuticals, positions it as a promising candidate for further investigation in the field of medicinal chemistry. As research in this area continues to evolve, the compound may contribute to the development of novel therapies with improved efficacy and safety profiles.

Further studies are needed to fully understand the biological activity and therapeutic potential of 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile. This includes comprehensive in vivo testing, elucidation of its mechanism of action, and assessment of its environmental impact. The continued exploration of fluorinated compounds like this one is essential for advancing the field of pharmaceutical science and developing more effective treatments for a wide range of medical conditions.

Overall, 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile exemplifies the growing importance of fluorine-containing compounds in drug discovery. Its unique structural features and potential biological activity make it a valuable subject for further research, with the possibility of contributing to the development of novel therapeutic agents. As the field of medicinal chemistry continues to advance, compounds like this one are likely to play an increasingly important role in the quest for more effective and targeted treatments.

Research on 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile is expected to yield important insights into the role of fluorine substitution in modulating the properties of organic compounds. These findings could have broader implications for the design of new drugs and the development of more effective therapeutic strategies. The continued investigation of compounds like this one is essential for advancing the field of pharmaceutical science and improving patient outcomes.

As the demand for more effective and selective therapeutic agents continues to grow, the potential applications of 5-Fluoro-2-(trifluoromethoxy)phenylacetonitrile are likely to expand. Future research should focus on optimizing its properties for specific therapeutic applications, as well as exploring its potential as a lead compound for the development of new drugs. The continued exploration of fluorinated compounds like this one is essential for advancing the field of medicinal chemistry and improving the treatment of various medical conditions.

Finally, the study of 5-Fluoro-2-(trifluorometh,oy)phenylacetonitrile underscores the importance of fluorine-containing compounds in modern pharmaceutical research. Its unique molecular structure and potential biological activity make it a valuable subject for further investigation, with the possibility of contributing to the development of novel therapeutic agents. As the field of medicinal chemistry continues to evolve, compounds like this one are likely to play an increasingly important role in the quest for more effective and targeted treatments.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)